Firebrick Pharma (ASX:FRE) founder and CEO Peter Molloy addressed investors this week around commercialisation of Nasodine, a nasal spray that kills cold and flu viruses without any potential for resistance.
The product developed from PVP-iodine (the same active ingredient in the antiseptic brand Betadine) and is available to Australians online.
Firebrick is already establishing other markets in the US, Singapore, Fiji, South Pacific and the Philippines.
Dr Molloy – who launched Betadine in Australia – speaks about how the human mindset has changed in relation to viruses since COVID. He says there’s also widespread fear of future pandemics.
“We’re on a quest,” he says.
“We have a moral, ethical obligation to make Nasodine available worldwide.”
Firebrick Pharma is a pharmaceutical developer focused on developing and commercialising novel formulations and uses of povidone-iodine.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。